The Societal Economic Impact of Secukinumab in First-Line Treatment of Moderate to Severe Plaque Psoriasis in Germany: An Open-Cohort Simulation.

Ahmed H SeddikNima MelzerFoteini TsotraDennis A Ostwald

Published in: PharmacoEconomics - open (2021)

This study demonstrated that using secukinumab instead of FAEs in moderate to severe plaque psoriasis could lead to substantial macroeconomic GVA gains.

Keyphrases

ankylosing spondylitis
coronary artery disease
high intensity
early onset
rheumatoid arthritis
atopic dermatitis
disease activity
virtual reality